Sawyer & Company Inc Acquires 7,773 Shares of Cencora, Inc. $COR

Sawyer & Company Inc bought a new position in Cencora, Inc. (NYSE:COR) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 7,773 shares of the company’s stock, valued at approximately $2,334,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Steph & Co. boosted its holdings in shares of Cencora by 23.5% in the first quarter. Steph & Co. now owns 168 shares of the company’s stock worth $53,000 after buying an additional 32 shares during the period. Cornerstone Wealth Group LLC grew its stake in Cencora by 1.6% in the first quarter. Cornerstone Wealth Group LLC now owns 2,434 shares of the company’s stock valued at $760,000 after purchasing an additional 38 shares in the last quarter. Pinnacle Associates Ltd. increased its position in Cencora by 1.8% in the 3rd quarter. Pinnacle Associates Ltd. now owns 2,203 shares of the company’s stock worth $662,000 after purchasing an additional 38 shares during the last quarter. OLD National Bancorp IN increased its position in Cencora by 0.4% in the 1st quarter. OLD National Bancorp IN now owns 9,964 shares of the company’s stock worth $3,130,000 after purchasing an additional 40 shares during the last quarter. Finally, Staley Capital Advisers Inc. increased its position in Cencora by 0.7% in the 1st quarter. Staley Capital Advisers Inc. now owns 6,127 shares of the company’s stock worth $1,925,000 after purchasing an additional 40 shares during the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on COR shares. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $330.00 price objective on shares of Cencora in a research report on Tuesday, September 8th. Argus boosted their target price on shares of Cencora from $340.00 to $380.00 and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings upgraded shares of Cencora from a “buy (b-)” rating to a “buy (b)” rating in a research note on Tuesday, October 6th. UBS Group lowered their target price on shares of Cencora from $430.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, October 16th. Finally, Wall Street Zen upgraded Cencora from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Fourteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $366.31.

Insider Activity at Cencora

In related news, EVP Elizabeth Campbell sold 11,300 shares of the firm’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the sale, the executive vice president owned 19,455 shares of the company’s stock, valued at approximately $6,305,754.60. This trade represents a 36.74% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.38% of the stock is currently owned by company insiders.

Trending Headlines about Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Argus raised its price target on Cencora from $340 to $380 and maintained a “buy” rating, implying additional upside and signaling confidence in the company’s outlook. Argus raises target for Cencora stock
• Positive Sentiment: The AON acquisition is strategically supportive because oncology is a growing healthcare market and the deal could broaden Cencora’s relationships with community-based providers. Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology
• Neutral Sentiment: UBS lowered its Cencora price target to $400, though the revised target remains above the recent trading level. The change suggests more cautious valuation assumptions rather than a clearly negative view. UBS cuts target to $400 for Cencora stock
• Negative Sentiment: The acquisition introduces execution, integration and financing risks. In addition, Brodsky & Smith announced an investigation involving American Oncology Network shareholders, which could add uncertainty around the transaction, although the notice does not specifically allege wrongdoing by Cencora. Brodsky & Smith shareholder update

Cencora Price Performance

Shares of NYSE:COR traded down $3.42 during midday trading on Wednesday, reaching $339.85. 407,425 shares of the company’s stock were exchanged, compared to its average volume of 1,466,199. The company’s 50 day simple moving average is $320.90 and its two-hundred day simple moving average is $303.66. The firm has a market capitalization of $64.85 billion, a PE ratio of 25.17, a price-to-earnings-growth ratio of 1.74 and a beta of 0.58. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.58 and a current ratio of 0.93.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, August 5th. The company reported $4.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.35 by $0.13. The firm had revenue of $84.75 billion during the quarter, compared to analyst estimates of $84.31 billion. Cencora had a return on equity of 125.45% and a net margin of 0.79%. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the prior year, the company posted $4.00 earnings per share. Equities research analysts expect that Cencora, Inc. will post 17.87 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Friday, August 14th were paid a $0.60 dividend. The ex-dividend date of this dividend was Friday, August 14th. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s dividend payout ratio is presently 17.83%.

Cencora Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.